Neoleukin Therapeutics In... (NLTX)
3.49
0.05 (1.45%)
At close: Dec 18, 2023, 9:00 PM
Company Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology.
The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019.
Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Neoleukin Therapeutics Inc.
| Country | United States |
| IPO Date | Mar 7, 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Donna M. Cochener-Metcalfe J.D. |
Contact Details
Address: 188 East Blaine Street Seattle, Washington United States | |
| Website | https://www.neoleukin.com |
Stock Details
| Ticker Symbol | NLTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001404644 |
| CUSIP Number | 64049K104 |
| ISIN Number | US64049K2033 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jonathan G. Drachman M.D. | Chief Executive Officer, Pres, Principal Financial Officer & Director |
| Sean Michael Smith | Interim Chief Financial Officer |
| Dr. Bill Arthur | Vice President & Head of Research |
| Dr. Carl Walkey Ph.D. | Senior Vice President of Corporation Devel. |
| Dr. David Baker | Co-founder & Member of Scientific Advisory Board |
| Dr. David Baker M.D., Ph.D. | Co-Founder |
| Dr. Priti Patel M.D., M.S. | Chief Medical Officer |
| Kamran Alam | Senior Strategic Advisor |
| Umut Ulge | Vice President of Clinical Devel. |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 14, 2025 | 8-K | Current Report |
| Apr 01, 2025 | 424B3 | Filing |
| Mar 28, 2025 | 4 | Filing |
| Mar 28, 2025 | 4 | Filing |
| Mar 28, 2025 | 4 | Filing |
| Mar 28, 2025 | 4 | Filing |
| Mar 24, 2025 | S-3 | Filing |
| Mar 24, 2025 | POS AM | Filing |
| Mar 24, 2025 | S-8 | Filing |
| Mar 24, 2025 | 8-K | Current Report |